Post hoc analysis of SCALE OBESITY and PREDIABETES and SCALE DIABETES trials for Saxenda (liraglutide)-Novo Nordisk

New data from a post-hoc analysis of the phase IIIa SCALE clinical development programme were presented at the 51st European Association for the Study of Diabetes (EASD) Annual Meeting. The data demonstrated that adults in the SCALE Obesity and Prediabetes and SCALE Diabetes trials who lost at least 5% of their body weight after completing 16 weeks of Saxenda (liraglutide 3 mg) treatment (defined as ‘early responders’) had greater weight loss after completing 56 weeks, compared with people losing less than 5% body weight with Saxenda after completing 16 weeks (‘early non-responders’). All treatment groups included a reduced-calorie diet and increased physical activity. After completing 16 weeks of the SCALE Obesity and Prediabetes trial, 67.5% of adults with obesity or who were overweight with weight-related comorbidities (excluding type 2 diabetes), were early responders to Saxenda (n=2487) and experienced an average weight loss of 11.5% after completing 56 weeks of treatment, compared with a weight loss of 3.8% for early non-responders. The proportion of early responders losing ?5%, >10% and >15% of their bodyweight after completing 56 weeks was 88.2%, 54.8% and 24.2% respectively (36.9%, 8.3% and 1.8% respectively for early non-responders). After completing 16 weeks of the SCALE™ Diabetes trial, 50.4% of adults with obesity or who were overweight and had type 2 diabetes, were early responders to Saxenda® (n=423), with a mean weight loss of 9.3% after completing 56 weeks of treatment compared with a weight loss of 3.6% for early non-responders. Across both trials, early responders demonstrated greater improvements in cardiometabolic risk factors, including blood pressure, cholesterol and triglycerides, compared to early non-responders.